BioSpace News Archive

Vizgen today announced the launch of its MERSCOPE ® Platform Grant Program, open to researchers in Europe and North America.

Intelligent Bio Solutions Inc. today announced plans to add the potent synthetic opioid drug, fentanyl, and fentanyl-adulterated street drugs, to the panel of substances detected by its lab-based confirmation testing using fingertip sweat collected by its proprietary Intelligent Fingerprinting Drug Screening System.

NanoViricides, Inc., reports that it has filed its Quarterly Report on Form 10-Q for the fiscal third quarter ending March 31, 2023 with the Securities and Exchange Commission on Monday, May 15, 2023.

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced its financial results for the first quarter of 2023 and provided a business update.

YS Biopharma Co., Ltd. today announced its PIKA Rabies Vaccine has received Phase 3 clinical trial approval from the Drug Regulatory Authority of Pakistan (“DRAP”).

Kimera® Labs Inc. is pleased to announce the FDA IND (Investigational New Drug) approval of its exosomes in a Phase I/IIa clinical trial.

Intergalactic Therapeutics announced today that it will host a virtual investor event with scientific experts in the fields of ophthalmology, bioengineering, and gene therapy on Tuesday, May 23, 2023 at 10:00 a.m. ET.

Covalon Technologies Ltd. today announced it is a silver sponsor of the 2023 Neonatal/Fetal Conference: From the Womb and Beyond being held both virtually and in-person in Columbus, Ohio from May 17 to 19, 2023.

Aviceda Therapeutics today announced the appointment of Patrick Johnson to its board of directors.

Inhibikase Therapeutics, Inc. today announced that the first patient has been dosed in its Phase 2 ‘201' trial evaluating IkT-148009, the Company’s novel Abelson Tyrosine Kinase, or c-Abl, inhibitor for the treatment of Parkinson’s disease.